5 Top HealthTech Startups Developing Cardiovascular Devices

We analyzed 184 HealthTech startups developing cardiovascular devices. Vesalius Cardiovascular, MOST Cardio, Aortyx, CroiValve & Orchestra BioMed develop 5 top solutions to watch out for. Learn more in our Global Startup Heat Map!

Our Innovation Analysts recently looked into emerging technologies and up-and-coming startups working on solutions for the healthcare sector. As there is a large number of startups working on a wide variety of solutions, we want to share our insights with you. This time, we are taking a look at 5 promising startups developing cardiovascular devices.

Heat Map: 5 Top Startups Developing Cardiovascular Devices

Using our StartUs Insights Platform, covering 1.116.000+ startups & emerging companies, we looked at innovation in the field of healthcare. For this research, we identified 184 relevant solutions and picked 5 to showcase below. These companies were chosen based on a data-driven startup scouting approach, taking into account factors such as location, founding year, and technology among others. Depending on your specific criteria, the top picks might look entirely different.

The Global Startup Heat Map below highlights 5 startups & emerging companies developing cardiovascular solutions. Moreover, the Heat Map reveals regions that observe a high startup activity and illustrates the geographic distribution of all 184 companies we analyzed for this specific topic.

Cardiovascular-Devices-Startups-Healthcare-Heat-Map-StartUs-Insights_noresize

Click to download

Which startups develop the other 179 solutions?

 

Vesalius Cardiovascular – Mitral Valve Repair

There is a significantly high risk of infection and other complications in open-heart surgery when replacing the mitral valve. Whereas, with the help of minimally invasive procedures like the Transcatheter Mitral Valve Replacement (TMVR), medical professionals correct mitral valve issues without any major surgeries. Minimally invasive procedures cost significantly less when compared to open-heart surgeries as the need to be hospitalized before and after the procedure drastically reduces. The pain is also comparatively lesser and helps the patient recover quickly. Startups and emerging companies develop cardiovascular devices to help medical professionals replace mitral valves in patients.

Canadian startup Vesalius Cardiovascular creates Calla, a transfemoral mitral valve repair system (TMVr). The startup’s biomedical device and delivery system enable percutaneous mitral valve repair. Its Orion TMVR (Transcatheter Mitral Valve Replacement) platform acts as an accessory to the TMVr procedure and optimizes valve replacement. In addition, Orion is also able to eliminate common risks including Left Ventricular Outflow Tract Obstruction (LVOTO) when repairing the mitral valve.

MOST Cardio – Reposable Design Platform

Angioplasty is the traditional way to treat peripheral artery disease – the buildup of plaque in the arteries. An atherectomy is a viable alternative to angioplasties to treat atherosclerosis, which is another form of cholesterol and fat build-up in the arterial walls. This encourages startups to develop minimally invasive endovascular solutions to tackle blocked arteries.

The US-based startup MOST Cardio develops cardiovascular surgical devices. The startup’s product portfolio includes proprietary guide wires with robotic guidance, proprietary catheters for plaque removal, and micro-emulsifiers to handle plaque emulsification. The startup also uses the femoral artery for minimally invasive surgeries that minimizes blood loss and potential infections. This solution further ensures that the arterial walls do not collapse or perforate while conducting the procedure.

Aortyx – Adhesive Endovascular Patch

Aortic dissections tear the arterial walls and result in a deviation of the flow of blood in the vessels. False lumen build-up further creates multiple aortic events like reduced cardiac performance or heart attacks. Advancement in material science enables startups to use a wide variety of microstructures with specific properties, such as elasticity, to develop solutions for efficiently closing arterial tears.

Spanish startup Aortyx offers an adhesive endovascular patch to treat the acute aortic syndrome, which causes a wide range of abnormalities in the aorta. The patch is bioresorbable and also progressively dissolves within 2 years. The viscoelastic nature of the microstructure enables the expansion and contraction of every cardiac cycle. The patch controls the clotting of the false lumen that avoids a peripheral malperfusion. Further, the startup utilizes an extracellular matrix (ECM) to help with the regeneration of the dissected part of the aorta.

CroiValve – Transcatheter For Tricuspid Regurgitation

Severe tricuspid regurgitation hinders the functioning of the right side of the heart by causing congestion in the heart chambers. Depending on the severity of the congestion, medical professionals find it difficult to suggest open-heart surgery for all patients. Startups develop medical device innovations in aortic valve repair and replacement such as the use of a transcatheter to help with tricuspid regurgitation.

Irish startup CroiValve is developing a novel transcatheter to treat the damaged tricuspid valve. The startup’s minimally invasive surgery uses a transcatheter to deliver a valve support mechanism to the tricuspid valve. A stent holds the superior vena cava in place just above the tricuspid valve. This results in the optimal functioning of the coronary valves and particularly reduces the risk of regurgitation.

Orchestra BioMed – Cardiovascular Drug Delivery

Coronary artery disease (CAD), arrhythmia, and heart failure are common cardiac problems that affect a majority of the global population. Technological advancements, specifically in robotics, imaging, and surgical devices, enable the healthcare industry to simplify surgical procedures. Startups are developing innovative drug delivery systems for resolving cardiac problems.

The US-based startup Orchestra BioMed develops a patented device, Virtue, a sirolimus-eluting balloon (SEB) to treat diseases related to the artery. Virtue helps the reduction of plaque in the arteries by utilizing a patented microporous balloon that acts as a drug delivery system. A proprietary bioabsorbable particle technology enables the startup to provide controlled delivery of sirolimus.

What About The Other 179 Solutions?

While we believe data is key to creating insights it can be easy to be overwhelmed by it. Our ambition is to create a comprehensive overview and provide actionable innovation intelligence that enables you to achieve your goals faster. The 5 cardiovascular device solutions showcased above are promising examples out of 184 we analyzed for this article. To identify the most relevant solutions based on your specific criteria, get in touch.

StartUs Insights logo

Discover our Free Healthcare Report 21 pages

DOWNLOAD
Discover the latest Healthcare Trends!
We'll deliver our free report straight to your inbox!



    Protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Looking for a custom analysis?
    Looking for a custom analysis?



      Protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Resources
      Discover the latest Healthcare Trends!
      We'll deliver our free report straight to your inbox!



        Protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

        Get a sneak peak into the future of Wearables!
        We'll contact you!



          Protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

          Discover the latest Manufacturing Trends!
          We'll deliver our free report straight to your inbox!



            Protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

            Discover the latest Pharma Trends!
            We'll deliver our free report straight to your inbox!



              Protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.